HRTX Earnings Date: Nov 9, 2026 (Estimated) — Heron Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is HRTX's next earnings date?
Heron Therapeutics, Inc. (HRTX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.03 on revenue of $37.5M.
How did HRTX do in its last earnings report?
In its most recent report on Aug 10, 2026 (Q2 2026), Heron Therapeutics, Inc. posted EPS of -$0.03 versus the -$0.01 estimate, a miss of 50.0%. Revenue was $37.7M against a $42.2M estimate. The stock's 1-day post-earnings move was -31.7%.
How much does HRTX stock move after earnings?
HRTX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 17.7% (up or down) in the day after earnings.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -0.01 | -0.03 | -50.00% | $37.7M | ❌ Miss | -31.74% | -31.40% | -28.69% |
| 2026-05-11 | Q1 2026 | -0.02 | -0.04 | -100.00% | $34.7M | ❌ Miss | -21.05% | -29.75% | -66.54% |
| 2026-02-26 | Q4 2025 | -0.03 | -0.02 | +33.33% | $40.6M | ✅ Beat | +11.11% | +4.63% | -23.60% |
| 2025-11-04 | Q3 2025 | -0.02 | -0.04 | -100.00% | $38.2M | ❌ Miss | -3.39% | -5.93% | +7.63% |
| 2025-08-08 | Q2 2025 | -0.01 | -0.02 | -100.00% | $37.2M | ❌ Miss | -28.26% | -26.63% | -29.35% |
| 2025-02-27 | Q4 2024 | -0.03 | 0.02 | +166.67% | $40.8M | ✅ Beat | +19.88% | +40.35% | +35.09% |
| 2024-08-06 | Q2 2024 | -0.04 | -0.06 | -50.00% | $36.0M | ❌ Miss | -25.09% | -23.60% | -32.58% |
| 2024-05-07 | Q1 2024 | -0.09 | -0.02 | +77.78% | $34.7M | ✅ Beat | +1.06% | -0.88% | +34.51% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $33.4M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| C I N V A N T I | 65.3% | $21.8M | -9.7% | $51.8M | $25.7M | $24.1M | $24.0M |
| Z Y N R E L E F | 33.1% | $11.1M | +35.0% | $14.3M | $8.0M | $8.2M | $9.3M |
| S U S T O L | 1.6% | $540K | -77.5% | $7.8M | $2.9M | $2.4M | $1.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.